NASDAQ:ABCL - AbCellera Biologics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $52.60
  • Forecasted Upside: 254.21 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$14.85
▼ -0.54 (-3.51%)

This chart shows the closing price for ABCL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AbCellera Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABCL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABCL

Analyst Price Target is $52.60
▲ +254.21% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for AbCellera Biologics in the last 3 months. The average price target is $52.60, with a high forecast of $59.00 and a low forecast of $45.00. The average price target represents a 254.21% upside from the last price of $14.85.

This chart shows the closing price for ABCL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in AbCellera Biologics.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/28/2021Berenberg BankReiterated RatingBuyMedium
5/14/2021Credit Suisse GroupLower Price TargetOutperform$53.00 ➝ $51.00Low
3/30/2021SVB LeerinkLower Price TargetIn-Line ➝ Outperform$52.00 ➝ $45.00Medium
3/30/2021Stifel NicolausLower Price TargetBuy$59.00 ➝ $55.00Medium
3/30/2021Berenberg BankReiterated RatingBuy$53.00Low
3/24/2021BMO Capital MarketsLower Price TargetOutperform$61.00 ➝ $59.00High
2/8/2021SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $52.00High
1/25/2021BMO Capital MarketsBoost Price Target$48.00 ➝ $61.00Low
1/5/2021Berenberg BankInitiated CoverageBuy$53.00N/A
1/5/2021Credit Suisse GroupInitiated CoverageOutperform$52.00N/A
1/5/2021Stifel NicolausInitiated CoverageBuy$59.00N/A
1/5/2021SVB LeerinkInitiated CoverageOutperform$45.00N/A
1/5/2021BMO Capital MarketsInitiated CoverageOutperform$48.00N/A
(Data available from 7/28/2016 forward)
AbCellera Biologics logo
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $14.85
Low: $14.51
High: $15.45

50 Day Range

MA: $21.99
Low: $14.85
High: $32.62

52 Week Range

Now: $14.85
Low: $14.51
High: $71.91

Volume

1,979,144 shs

Average Volume

1,690,898 shs

Market Capitalization

$4.02 billion

P/E Ratio

33.00

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of AbCellera Biologics?

The following Wall Street analysts have issued reports on AbCellera Biologics in the last twelve months: Berenberg Bank, BMO Capital Markets, Credit Suisse Group AG, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for ABCL.

What is the current price target for AbCellera Biologics?

5 Wall Street analysts have set twelve-month price targets for AbCellera Biologics in the last year. Their average twelve-month price target is $52.60, suggesting a possible upside of 254.2%. BMO Capital Markets has the highest price target set, predicting ABCL will reach $59.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $45.00 for AbCellera Biologics in the next year.
View the latest price targets for ABCL.

What is the current consensus analyst rating for AbCellera Biologics?

AbCellera Biologics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABCL will outperform the market and that investors should add to their positions of AbCellera Biologics.
View the latest ratings for ABCL.

What other companies compete with AbCellera Biologics?

How do I contact AbCellera Biologics' investor relations team?

The company's listed phone number is 604 559 9005. The official website for AbCellera Biologics is www.abcellera.com.